Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search results
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
In this article, we hear Colin's story and the reasons why he has hope for the future.
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
Our Peer Support Groups are growing. Find out more about what's planned for the future.
If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Thursday 19 September, 11.00am - In-person - Please come and join us for a guided tour of the new 'Seeing Differently' exhibition at the MK Gallery.
Our monthly e-Newsletter featuring the latest updates from Retina UK.